- Home
- LTC vs AGIO Comparison
LTC vs AGIO Comparison
Compare LTC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- AGIO
- Stock Information
- Founded
- LTC 1992
- AGIO 2007
- Country
- LTC United States
- AGIO United States
- Employees
- LTC N/A
- AGIO N/A
- Industry
- LTC Real Estate Investment Trusts
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- LTC Real Estate
- AGIO Health Care
- Exchange
- LTC Nasdaq
- AGIO Nasdaq
- Market Cap
- LTC 1.6B
- AGIO 1.4B
- IPO Year
- LTC 1992
- AGIO 2013
- Fundamental
- Price
- LTC $35.28
- AGIO $39.05
- Analyst Decision
- LTC Hold
- AGIO Buy
- Analyst Count
- LTC 5
- AGIO 6
- Target Price
- LTC $37.80
- AGIO $58.60
- AVG Volume (30 Days)
- LTC 355.4K
- AGIO 626.2K
- Earning Date
- LTC 07-28-2025
- AGIO 07-31-2025
- Dividend Yield
- LTC 6.52%
- AGIO N/A
- EPS Growth
- LTC 0.36
- AGIO N/A
- EPS
- LTC 1.93
- AGIO 11.45
- Revenue
- LTC $202,686,000.00
- AGIO $37,035,000.00
- Revenue This Year
- LTC N/A
- AGIO $22.30
- Revenue Next Year
- LTC $11.33
- AGIO $219.19
- P/E Ratio
- LTC $18.29
- AGIO $3.41
- Revenue Growth
- LTC 3.98
- AGIO 25.96
- 52 Week Low
- LTC $31.70
- AGIO $23.42
- 52 Week High
- LTC $39.89
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- LTC 51.84
- AGIO 70.00
- Support Level
- LTC $34.90
- AGIO $34.60
- Resistance Level
- LTC $35.81
- AGIO $40.06
- Average True Range (ATR)
- LTC 0.55
- AGIO 1.49
- MACD
- LTC 0.05
- AGIO 0.43
- Stochastic Oscillator
- LTC 66.83
- AGIO 86.59
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.